Kureha Corporation

Kureha is a mid-cap Japanese specialty chemicals and plastics maker with a strong technology base. It sells about ¥162bn a year and has built global niche positions from in-house polymer and carbon chemistry.

Advanced Materials: holds most of its strategic value:

• PVDF (polyvinylidene fluoride), used mainly as a cathode binder in lithium-ion batteries;

• PPS resin through its 50:50 US joint venture with Celanese (Fortron Industries);

• PGA (polyglycolic acid) dissolvable frac plugs for US shale gas;

• pitch-based carbon fibre and bead-shaped activated carbon.

Specialty Plastics: contributes stable, high-margin cash flow from the household franchise NEW Krewrap and Seaguar fluorocarbon fishing line.

Specialty Chemicals: combines regional chlor-alkali and chlorobenzene chemistry with a small life-science arm: the fungicides metconazole and ipconazole, the kidney drug Kremezin, and a pipeline led by the fungicide carmeconazole.

After a PVDF-led capex cycle failed when EV demand slowed, Kureha took ¥36.5bn of impairments in FY2025. It has since reset its strategy around a three-pillar portfolio, targeting ROE of 8% by FY2028 and 12% by FY2035.

---

Company's own description. The FY2025 Summary describes the Kureha Group as manufacturing and selling advanced materials, chemical materials and specialty plastics as its core business. It also provides construction and facility repair for its segments, logistics, environmental solutions and other services. The corporate vision (2023) is to be "a specialty solutions company that leverages proprietary technology and contributes to a new future for society." The FY2035 plan restates the aim as becoming "a high-value-added company committed to driving value through technology and competing globally."

Business model. Kureha is overwhelmingly a product company:

• Revenue is recognised on shipment of resins, compounds, processed parts (PGA frac plugs), films, consumer goods, agrochemical active ingredients and formulations, a pharmaceutical, and commodity chlorine chemicals.

• Service revenue comes from two places:

  • the Construction segment (Kureha Construction, mostly external civil and building contracts plus internal plant work);

  • Other Operations, which covers industrial waste treatment (Kureha Ecology Management), analysis and testing, logistics (Kureha Unyu) and medical services.

• Together these service businesses made up about 21% of FY2025 external revenue (¥34.2bn of ¥161.7bn).

• Licensing and royalties are not separately disclosed. Agrochemical active ingredients are commercialised largely through partner distribution and licensing arrangements, but royalty income is not broken out.

• There is no subscription revenue.

Value-chain position.

• Kureha is vertically integrated from basic chlorine chemistry at Iwaki (caustic soda, hydrochloric acid and chlorinated aromatics) into fluoropolymer and chlorinated-polymer monomers. These monomers feed PVDF and PVDC (Krehalon/Krewrap).

• It is a mid-stream materials supplier to battery cell makers (PVDF binder), compounders and auto/electronics component makers (PPS), and oilfield service companies and E&Ps (PGA plugs).

• It is a downstream brand owner in Japanese household consumables (NEW Krewrap) and global fishing line (Seaguar).

• In crop protection it acts as an originator of active ingredients and partners with distributors.

Customer types and end-markets.

• Battery cell makers: Japan, Korea and China customers for automotive NMC/LFP and energy storage systems (ESS).

• Automotive and electronics tier suppliers, including PPS for optical communication components in data centres.

• US shale oil and gas operators (Haynesville, Appalachia, Eagle Ford, Bakken, Permian), with planned exports to Argentina and the Middle East from FY2026.

• Global agrochemical distributors.

• Japanese nephrology practices and wholesalers (Kremezin).

• Japanese retailers (home products).

• Global anglers and tackle distributors (Seaguar).

• Meat and cheese processors (Krehalon PVDC barrier film and bags; the European multilayer heat-shrink film business was exited in 2024).

• Japanese municipalities and industry (waste treatment, construction).

Independent characterisation. Kureha is best described as a portfolio of niche technology franchises attached to a regional chemical and services base:

• Its profit pool is unusually concentrated in a few products. In FY2025, Specialty Plastics generated about 48% of segment core operating profit on 23% of revenue (LTMP 2035).

• Its growth narrative from 2021 to 2024 rested on a single application: PVDF binder for automotive NMC batteries.

• When that application faltered, through EV subsidy cuts in Europe and the US and a market shift to LFP chemistry, the economics of a ¥66–70bn capacity expansion collapsed.

• The company is now an earnings-recovery and capital-allocation story. Investors are asking whether PGA can return to profit, whether PVDF can fill a new 8,000 t/y plant from 2027, and whether a long-dated life-science pipeline can rebalance the portfolio by 2035.

Corporate philosophy and vision (2023).

Philosophy: value people and nature; continuously transform and grow; create valuable products and technologies for a sustainable society.

Vision: "a specialty solutions company that leverages proprietary technology and contributes to a new future for society."

Management objectives: continuous enhancement of economic value; contribution to resolving social issues; contribution to reduced environmental impact.

Priority measures: reviving Kureha's technology-driven focus; strengthening the management base; synergism between company and employees.

Strategic evolution.

Management's own diagnosis (LTMP 2035).

External causes: sharp cuts in European and US environmental subsidies; automakers' resulting shift in EV strategy; the rapid rise of Chinese manufacturing.

Internal causes: a plan "overly dependent on PVDF business profits"; misjudging the NMC-to-LFP shift; underestimating LFP technology innovation; misjudging PGA development time.

FY2028 segment targets:

The core OP bridge from ¥14.5bn to ¥19.0bn is +3.9bn from Advanced Materials (PGA +3.3bn is the largest single item; "PVDF continues to face a challenging earnings situation due to increased depreciation"), +0.6bn from Specialty Plastics, –0.4bn from Specialty Chemicals, –1.1bn from Construction & Others, and +1.5bn from Production Transformation.

FY2035 aspirations:

• ROE 12%; ROIC 8%.

• Earnings mix of about 30% Advanced Materials, 30% Specialty Plastics, 30% Specialty Chemicals and 10% Construction/other, versus 29/48/9/15 in FY2025 (company slide).

• Life Science revenue of about ¥40bn, from roughly ¥10–15bn historically.

• New-product revenue of at least ¥20bn and a new-product ratio of at least 10%.

• Three business clusters each at ¥40bn or more of revenue: crop protection/agri-inputs, home products, and PVDF/PGA.

• Pipeline FY2035 revenue targets as printed: carmeconazole ¥20bn (peak ¥25bn), biostimulant ¥12bn (¥14bn), anti-adhesion film ¥4bn (¥10bn), bio-pesticides ¥2bn (¥5bn).

Analyst flag on the pipeline figures: the pipeline targets add up to ¥38bn. Adding existing Life Science revenue (about ¥10.5bn) gives more than the stated ¥40bn Life Science goal. Either the pipeline figures are peak-scenario and partly replace existing sales, or there is a unit/translation inconsistency (億円 vs billion yen). Treat them as indicative until clarified.

Business strategies by line:

PVDF: - full-scale entry into LFP for both ESS (already about 20% of PVDF sales, with a data-centre ESS focus) and EV (Chinese and Korean projects, shipments 1H–mid FY2027);

• a next-generation NMC grade adopted for new Japanese EV/LiB projects (FY2028);

• industrial expansion into semiconductor equipment and water treatment;

• an "optimal production framework" before the new plant starts in 2027.

PGA: - grow sales in medium/high-temperature gas fields (data-centre power and LNG exports);

• launch low and ultra-low temperature grades;

• convert 90% of plugs to short type by FY2028;

• begin shipments to Argentina and the Middle East in FY2026;

• fundamental review if not profitable in FY2026.

Home products: five-brand kitchen-consumables portfolio; rebranding; launch of a new brand; TV and social-media promotion; area-based marketing.

Seaguar: successor to Grandmax; PFAS-compliant line; tuna-line recycling.

Life Science: stage-gate management; AI-enabled active-ingredient discovery; partnerships with start-ups and universities; M&A to expand the pipeline.

Production Transformation Project: automation, workforce optimisation and new grades through stronger production technology, contributing about ¥1.5bn of core OP by FY2028.

ROIC management: segment-level balance sheets.

Core operating profit: was adopted as the main KPI from FY2026.

Shareholder return policy. DOE was introduced at 5% from FY2025 and is maintained at 5% for FY2026 and beyond, though it may be flexibly reviewed if conditions change. Treasury stock is capped at about 5% of issued shares, with any excess cancelled.

ESG and organisational initiatives:

• CO2 reduction of at least 30% by FY2030 versus FY2013, with a path via biomass co-firing and less coal;

• carbon neutrality by 2050;

• landfill rate target of 1.5% (achieved FY2025);

• Health & Productivity Outstanding Organization for six consecutive years;

• METI DX certification (Sep 2025);

• new Risk Management and Sustainability Promotion Committees with all executive officers as members;

• an internal job-posting system.

Pricing is not disclosed for any product. Launch years marked † are from secondary knowledge and indicative only.

Advanced Materials

Specialty Chemicals

Specialty Plastics

Construction and Other Operations

New-business technologies (pre-commercial)

Disclosed by the New Business Division (LTMP 2035):

• low-molecular-weight PFAS detoxification technology (disclosed 2024);

• a bio-pesticide and microbial-interaction analysis platform (2025);

Liquid Crystal Polymer (LCP): technology (2026);

• SiC fibre;

touch-panel: materials.